Article

VIDEO: Roman Hovorka, PhD, Talks About the Cost and Coverage Issues Associated with Continuous Glucose Monitoring

Roman Hovorka, PhD, talks about the prohibitive costs in continuous glucose monitoring. He states that if these costs can be reduced there will be wider acceptance and therefore a benefit to diabetes care.

Roman Hovorka, PhD, talks about the prohibitive costs in continuous glucose monitoring. He states that if these costs can be reduced there will be wider acceptance and therefore a benefit to diabetes care.

According to Hovorka, there are more issues in the United Kingdom compared to the United States at this time, although the costs of of continuous glucose monitoring prohibit widespread use in both countries.

Related Videos
Marla Black Morgan, MD, Phoebe Neurology Associates
Sam Peasah, PhD, MBA, RPh, director for the Center of High-Value Health Care at the University of Pittsburgh Medical Center (UPMC)
Bridgette Picou, LVN, ACLPN, The Well Project
Laura Bobolts, PharmD, BCOP, senior vice president of clinical strategy and growth at OncoHealth
Adam Colburn, JD, associate vice president for congressional affairs, AMCP
Richard Nowak, MD, MS, Yale School of Medicine
AMCP Recap 2025
Giulio Cossu, MD
Lynae Darbes, PhD
Kimberly Westrich, MA, chief strategy officer at the National Pharmaceutical Council
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo